Get started
Markets US Stocks Health Technology Medical Specialties

Better Therapeutics, Inc BTTX

BTTXNASDAQ
BTTX
Better Therapeutics, IncNASDAQ
See more on advanced chartSee more on advanced chart
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on advanced chartSee more on advanced chart
Overview
News Ideas Financials Technicals Forecast

BTTX chart

Ideas

BTTX top authors
Rocky88888888888
Rocky88888888888 Premium
Follow Following Unfollow
When to up your share size?
BTTX
, 15Education
BTTX: When to up your share size?

Many traders have 2 or more trade set ups. It is important to know the following: 1)The risk of your trade must be in accordance with the winning percentage of the trade set up. 1)Your share size should increase or decrease in accordance with the winning percentage of the trade set up. * Share size increase must be in accordance to you account size (account...

$BTTX entry PTs 1.30-1.40 Long term PT 17-50 and higher
BTTX
, 1DLong
BTTX: $BTTX entry PTs 1.30-1.40 Long term PT 17-50 and higher

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive...

$BTTX
BTTX
, 1DLong
BTTX: $BTTX

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive...

Potential double bottom?
BTTX
, 60Long
BTTX: Potential double bottom?

This is a ticker I'm following closely. Look at the fib level and potential double bottom. Promising!

Technicals

Analyst rating

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins}
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Medical Specialties
Better Therapeutics, Inc. develops software-based prescription digital therapeutics for treating diabetes, heart disease, and other cardiometabolic conditions. It engages in developing a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The company was founded by Kevin J. Appelbaum and David P. Perry in April 2015 and is headquartered in San Francisco, CA.

News flow

More news